<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Health Net, Inc. Provides Coverage for Biodesix’ VeriStrat Test 

    HealthNet now covers Biodesix' VeriStrat test

    Biodesix Receives Positive Coverage from Cigna for VeriStrat Test

    Biodesix' VeriStrat test is covered by Cigna

    Biodesix Raises Follow-On Series E Financing

    Biodesix raises follow-on series E financing

    Biodesix Receives CareFirst BlueCross BlueShield (BCBS) Coverage for VeriStrat Test

    Biodesix' VeriStrat test has won approval from CareFirst BlueCross BlueShield

    Biodesix Adds Biognosys’ Proteomics Technology To Its Diagnostic Development Capabilities; Collaboration Enables Protein Identification Within Proteomic Signatures

    Biodesix recently added Biognosys' Proteomics to their capabiltites.

    Biodesix Named To Inc. 500|5000 Fastest-Growing Private Companies List

    Biodesix named to Inc. 500|5000 Fastest-Growing Private Companies list

    Biodesix And Inivata To Investigate Clinical Utility Of Next Generation Sequencing-Blood Based Tests For Patients With Advanced Lung Cancer

    Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.

    Lung Cancer Journal: VeriStrat Proteomic Test Improves Overall Survival and Decreases Medical Costs for Patients with Advanced NSCLC

    The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.

    Aetna Provides Coverage for Biodesix’ VeriStrat Test

    Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.

    Biodesix Raises Additional Series E Financing

    In addition to the $15 million of series shares in 2013 and 2014, Biodesix brought in another $12 million, for total proceeds of $27 million from the sale.